Tweet
Wouldn't this be easier to release since the active ingredient is already available in a similar thing and approved? So safety in dose would be the thing they would have to prove? Did read the company was in a lawsuit against generic brands and the money breakdown showed the generic brands was making just as much money. Over the years have seen plenty of shampoos claim to 'promote hair growth' and show a in house clinical trial as ref. It's all about wording to a lot of them so they can get away with it.
-
-
@2014... Im not as certain as i was about bim being the new product in texas. They released this news yesterday for their new product "dry eye." Hopefully, they are still moving forward and we will find out in two weeks time.
Comment
-
iNo, I know. They included an image of the product and its packaging, it's in the same exact greenish bottle and box as the other "Refresh" dry eye products. It's definitely not new packaging. It's a tweak to a product they already have with new labelling, but certainly not new packaging.
They spent $7.5 million for new processing equipment to make new packaging. This means that whatever the product is, it has to be new packaging for a drug they already make.
By the way, I would just like to include that their Q3 2015 and R&D key pipeline update is taking place from their Irvine campus, which I found out is the base for their medical aesthetics unit. This is not random. They chose this location for a reason. Makes literally no sense to have presentations and a reception at the base of their medical aesthetics unit, to talk about or launch products for eye care, gastro-intestinal, women's health, urology or drugs for mental health. Everything a corporation like this does is very calculated and thoroughly planned. Which is why when they list bim a few months before this event (from the base of their medical aesthetics unit), I get suspicious. I also think their CEO tweeting out that they are "committed to expanding the aesthetic market for men," is deliberate. As it stands, tackling hair loss would be huge, because most men don't get botox or dermal fillers (unless you're on TV, but that number is very low in terms of an entire market).Comment
-
2014 are you Fox Mulder? Some of your posts lead me to think so
Although I do hope you are right, as we are all desperate for some good news about a decent new treatment that actually works.
Comment
-
Well, when it comes to bim, it's now a question of "when" rather than "if."
I think the Waco news is very interesting, as is the Q3 and pipeline update event taking place at their base for medical aesthetics. Also having the CEO tweeting out (and he doesn't tweet that much) that they are "committed to expanding the aesthetics market for men," is interesting. It's all now a question of "when," and given how things seem to be developing, I'd say they are very close.Comment
-
What makes you so confident in this statement? Because the CEO tweeted "committed to expanding the aesthetic market for men" and because they're working on some new packaging? Don't get me wrong, I truly hope you are correct, but it seems a bit too soon to say that this will definitely be coming to market.
The thing with bimatoprost is that it's expensive. As a result, the results are going to have to be a lot better than minoxidil in order to justify the extra expense for the average consumer. If it does work, we're all going to be penniless.Comment
-
What makes you so confident in this statement? Because the CEO tweeted "committed to expanding the aesthetic market for men" and because they're working on some new packaging? Don't get me wrong, I truly hope you are correct, but it seems a bit too soon to say that this will definitely be coming to market.
The thing with bimatoprost is that it's expensive. Therefore, the results are going to have to be a lot better than minoxidil in order to justify the extra expense for the average consumer. If it does work, we're all going to be penniless.Comment
-
[QUOTE=Hubris;221335]What makes you so confident in this statement? Because the CEO tweeted "committed to expanding the aesthetic market for men" and because they're working on some new packaging? Don't get me wrong, I truly hope you are correct, but it seems a bit too soon to say that this will definitely be coming to market.
The thing with bimatoprost is that it's expensive. Therefore, the results are going to have to be a lot better than minoxidil in order to justify the extra expense for the average consumer. If it does work, we're all going to be penniless
AgreedComment
-
Well, you cherrypicked what I included in my last post. I'm very confident about how close they are for a number of reasons, not just the ones you mention.
Start with the chart of the 70+ mid to late stage programs that they are moving forward with (also means continuing development) in their Q2 2015 presentation. (You can look for the presentation on this page - http://ir.allergan.com/phoenix.zhtml...-presentations) Download the PDF for the Q2 2015 presentation and go to page 23 of the presentation. You will find a chart which lists their drugs that are closest to launch, and I know this because I looked up each of these drugs in the chart, and all have them have either launched recently, are scheduled to launch in late 2015/early 2016, or are well into phase 3. The chart does indicate that these are the closest to release among their mid-to-late stage projects. Bim was included in this presentation after over a year of quiet when everyone thought it was dead, because of how quiet it got. Three months from this Q2 presentation, we have their pipeline update and Q3 presentation from the center of Allergan's Medical Aesthetics Unit. Yes, bim falls under medical aesthetics for men.
You're also ignoring the fact that the new machines to create new packaging cost $7.5 million (not peanuts). Also, this plant is most likely the largest producer of bimatoprost for Allergan in the country, maybe the world, with 22,000 Sq ft devoted to Latisse production alone. That doesn't even include Lumigan, which is also produced at that plant. I'm not saying I'm certain that bim is the drug, but I think it's very likely.
Yes bim is expensive, but if it is manufactured and distributed on a global scale (which is what they are claiming to do with this new drug, as listed in the article), it brings the price down. If minox is $30 for bottle (or one month of use) and if bim works noticeably better, but anywhere on the scalp, I think a higher price is definitely justified. Also, according to data in their trials, once a desired hair thickness is achieved, bim can be used once or twice a week to maintain on those areas. Bimatoprost has shown in human hair studies to increase cell-to-cell signaling, which protects against the ravages of DHT. If they really want to take market share from their biggest competition - fin and minox, they'd better adjust the price to be somewhat reasonable for the masses. Let's not forget that something like this is a luxury.
I've posted this stuff before, please go back and read previous posts of mine so I don't have to keep doing it. I'm happy to answer questions or doubts, but it gets tiring because I've literally posted this stuff 3 times or so.Comment
-
And if this isnt announced at their upcoming shareholder update, then you just keep saying its coming but push the timeline further back?
I just think that if this were actually working we would have seen aggressive trials like what sammumed has been doing w SM. I'm Way more confident they have something of use then the folks at allergen doComment
-
No, no i think ill stay here. I like seeing how mad you get when someone disagrees w your speculations
the only way I can see your theory playing out is if allergen has been preparing for the 21st century cures act and stalling until it gets passed. that way they may be able to skip phase 3 and save a boatload of money. then that might explain why their test has been on holdComment
-
Hey guys today i read pfizer and allergan will join toghter with a fusion, good or bad? Can we ****ig have 6 months without acquisitions?Comment
Comment